Last reviewed · How we verify

NCT03798314

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Completed Phase 1 Last updated 6 January 2023
What this trial tests

Phase 1 trial testing Nivolumab in Recurrent Nervous System Lymphoma in 3 participants. Completed in 15 September 2021.

Timeline
30 January 2019
Primary endpoint
30 December 2020
15 September 2021

Quick facts

Lead sponsorMayo Clinic
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment3
Start date30 January 2019
Primary completion30 December 2020
Estimated completion15 September 2021
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Recurrent Nervous System Lymphoma or Recurrent Primary Vitreoretinal DLBCL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to treatment. Immunotherapy with monoclonal antibodies, such as pomalidomide and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
  2. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments.
    Jung YJ, Tweedie D, Scerba MT, Greig NH. · · 2019 · cited 116× · PMID 31867326 · DOI 10.3389/fcell.2019.00313
  3. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
    Marcelis L, Antoranz A, Delsupehe AM, Biesemans P, et al · · 2020 · cited 50× · PMID 32335702 · DOI 10.1007/s00262-020-02575-y
  4. Update on Novel Therapeutics for Primary CNS Lymphoma.
    Schaff LR, Grommes C. · · 2021 · cited 15× · PMID 34771535 · DOI 10.3390/cancers13215372
  5. Checkpoint inhibition in hematologic malignancies.
    Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172
  6. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J, Sayyed A, Darweesh M, Kaloyannidis P, et al · · 2020 · cited 13× · PMID 33178841 · DOI 10.1155/2020/9350272
  7. Ikaros Proteins in Tumor: Current Perspectives and New Developments.
    Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
  8. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?
    Jeong AR, Ball ED, Goodman AM. · · 2020 · cited 9× · PMID 33447123 · DOI 10.1177/1179554920976366

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03798314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing